New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure
Trial ID or NCT#
Status
NOT RECRUITING
Purpose
This study is being done to compare the effects of bucindolol hydrochloride (bucindolol) to metoprolol succinate (Toprol-XL) on the recurrence of symptomatic atrial fibrillation/atrial flutter in patients with heart failure who have a specific genotype for the beta-1 adrenergic receptor.
Official Title
GENETIC-AF - A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients With Heart Failure
Eligibility Criteria
- - Must weigh at least 40 kg
- - Possess the β1389 Arg/Arg genotype
- - Left Ventricular Ejection Fraction (LVEF) < 0.50 assessed within 12 months prior to Screening
- - At least one episode of symptomatic paroxysmal or persistent AF within 180 days of Screening
- - Clinically appropriate for electrical cardioversion (ECV) if AF/AFL is present after study drug initiation
- - Receiving appropriate anticoagulation therapy prior to Randomization
- Key
- - NYHA Class IV symptoms at the time of Randomization
- - Significant fluid overload at Randomization
- - Permanent AF at Screening
- - More than two previous ECV within 6 months of Randomization or if the most recent ECV failed to produce SR
- - Presence of an LVAD, or likely to requirement LVAD placement within 6 months of Randomization
- - History of a successful atrioventricular (AV) node ablation
- - History of an AF/AFL ablation within 30 days of Randomization
- - Evidence of an appropriate firing of an implanted cardioverter-defibrillator (ICD) device for ventricular tachycardia (VT) or ventricular fibrillation (VF) within 90 days of Randomization